CA2979226A1 - Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same - Google Patents

Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same Download PDF

Info

Publication number
CA2979226A1
CA2979226A1 CA2979226A CA2979226A CA2979226A1 CA 2979226 A1 CA2979226 A1 CA 2979226A1 CA 2979226 A CA2979226 A CA 2979226A CA 2979226 A CA2979226 A CA 2979226A CA 2979226 A1 CA2979226 A1 CA 2979226A1
Authority
CA
Canada
Prior art keywords
expression level
prostate cancer
whole blood
col1a1
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2979226A
Other languages
English (en)
French (fr)
Inventor
Deborah Ricci
Michael Gormley
Shibu THOMAS
Yashoda RAJPUROHIT
Michael Schaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2979226A1 publication Critical patent/CA2979226A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2979226A 2015-03-12 2016-03-11 Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same Abandoned CA2979226A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132064P 2015-03-12 2015-03-12
US62/132,064 2015-03-12
PCT/US2016/022004 WO2016145308A2 (en) 2015-03-12 2016-03-11 Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same

Publications (1)

Publication Number Publication Date
CA2979226A1 true CA2979226A1 (en) 2016-09-15

Family

ID=55642872

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979226A Abandoned CA2979226A1 (en) 2015-03-12 2016-03-11 Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same

Country Status (19)

Country Link
US (1) US20160304962A1 (sl)
EP (1) EP3268493B1 (sl)
JP (1) JP2018507702A (sl)
KR (1) KR20170136525A (sl)
CN (1) CN107567502A (sl)
CA (1) CA2979226A1 (sl)
CY (1) CY1125020T1 (sl)
DK (1) DK3268493T3 (sl)
ES (1) ES2905163T3 (sl)
HR (1) HRP20220128T1 (sl)
HU (1) HUE058025T2 (sl)
IL (1) IL254119A0 (sl)
LT (1) LT3268493T (sl)
MA (1) MA45480A (sl)
PL (1) PL3268493T3 (sl)
PT (1) PT3268493T (sl)
RS (1) RS62972B1 (sl)
SI (1) SI3268493T1 (sl)
WO (1) WO2016145308A2 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2954456T3 (es) 2015-03-25 2023-11-22 Massachusetts Gen Hospital Análisis digital de células tumorales circulantes en muestras de sangre
CN110050075B (zh) * 2016-10-27 2024-04-02 通用医疗公司 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
CN107338319A (zh) * 2017-08-25 2017-11-10 天津艾至恩医疗科技有限公司 一种核苷酸引物及预测前列腺癌去势术预后的基因多态性检测试剂盒
CN110760585B (zh) * 2019-11-07 2022-12-09 深圳市华启生物科技有限公司 前列腺癌生物标志物及其应用
CN111500728A (zh) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 检测人ar-v7及ar基因表达的引物探针组合物、试剂盒及检测方法
WO2023220314A1 (en) * 2022-05-12 2023-11-16 Veracyte SD, Inc. Prognosis and treatment of molecular subtypes of prostate cancer
KR20240022906A (ko) * 2022-08-12 2024-02-20 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721506C (en) * 2008-04-16 2019-09-17 Jun Luo Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
WO2014028925A1 (en) * 2012-08-17 2014-02-20 Memorial Sloan-Kettering Cancer Center Gene expression profile associated with prostate cancer
EP2971101A2 (en) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers

Also Published As

Publication number Publication date
HUE058025T2 (hu) 2022-06-28
CN107567502A (zh) 2018-01-09
ES2905163T3 (es) 2022-04-07
WO2016145308A3 (en) 2016-10-13
MA45480A (fr) 2018-01-17
CY1125020T1 (el) 2023-03-24
JP2018507702A (ja) 2018-03-22
KR20170136525A (ko) 2017-12-11
WO2016145308A2 (en) 2016-09-15
US20160304962A1 (en) 2016-10-20
HRP20220128T1 (hr) 2022-04-29
PL3268493T3 (pl) 2022-05-09
IL254119A0 (en) 2017-10-31
SI3268493T1 (sl) 2022-04-29
EP3268493A2 (en) 2018-01-17
DK3268493T3 (da) 2022-03-07
EP3268493B1 (en) 2022-01-05
RS62972B1 (sr) 2022-03-31
LT3268493T (lt) 2022-03-10
PT3268493T (pt) 2022-04-13

Similar Documents

Publication Publication Date Title
EP3268493B1 (en) Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
JP6745820B2 (ja) 前立腺がん予後判定の方法
WO2014160645A2 (en) Neuroendocrine tumors
US9952221B2 (en) Methods for screening, predicting and monitoring prostate cancer
US11667909B2 (en) Diagnosis of prostate cancer
WO2010088688A2 (en) Diagnosis of in situ and invasive breast cancer
WO2017040520A1 (en) Molecular methods for assessing urothelial disease
WO2018219264A1 (zh) 一种长链非编码rna作为前列腺癌分子标志物的应用
US20090215058A1 (en) Methods for screening, predicting and monitoring prostate cancer
EP2373816B1 (en) Methods for screening, predicting and monitoring prostate cancer
US20130210665A1 (en) Method and kit for the diagnosis and/or prognosis of tolerance in liver transplantation
CN113249479B (zh) 胰腺癌相关的lncRNA标志物、探针及检测试剂盒在胰腺癌诊断中的应用
WO2011012691A2 (en) Processes and methods for diagnosis of alzheimer's disease
US20170335399A1 (en) Detection of mineralocorticoid receptor activation and personalized antihypertensive therapy based thereon
KR102229647B1 (ko) 신장이식 환자의 급성거부반응 진단용 miRNA 바이오 마커 및 이의 용도
US20070281305A1 (en) Detection of lymph node metastasis from gastric carcinoma
EP4317458A1 (en) Follicular thyroid cancer-specific marker
JP5170734B2 (ja) がんの検査に使用する遺伝子のスクリーニング方法と遺伝子セット
CN116121369A (zh) 肾癌相关生物标志物及其应用和检测方法
CZ30300U1 (cs) Sada pro neinvazivní diagnostiku karcinomu močového měchýře na bázi močových mikroRNA

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220601

FZDE Discontinued

Effective date: 20220601